Category: Forbes

This Week In XR: VR’s Big IAAPA, New Rift, Augmented Workers, Surgical Scores Mayo Clinic, Cash

XR news that caught my eye this week.

President Trump: Robert Bowers Is A Terrorist, Not A Person With Dementia

Twelve hours after Robert Bowers murdered 11 people at the Tree of Life Congregation, President Trump described Bowers as “sick,” evil,” and “demented.” By lumping those descriptions together, Trump not only perpetuates a falsehood, but also further st…

One Way To Reduce Opioid Use After Surgery: Know That It Will Hurt

Patient education regarding how much pain to expect following surgery may help reduce unnecessary opioid prescriptions, and may, in turn, help in decrease opioid-related addictions and deaths.

How One Startup Is Using AI To Find Cures For 100 Rare Diseases By 2025

It’s believed that around 350 million people suffer from rare diseases, and previously finding cures has been almost impossible. Find out how one startup is harnessing the power of machine learning and artificial intelligence to change this.

DNA Sequencing Giant Illumina Will Buy Pacific Biosciences For $1.2 Billion – Exclusive CEO Interview

Illumina, the dominant maker of DNA sequencing machines, has agreed to purchase smaller rival Pacific Biosciences for $8 a share, or $1.2 billion, in an effort to cement its ownership of cutting-edge genetic research.

Healthy Breathing Is Gaining Ground As An Industry Trend

Here’s what O2TODAY and others are doing to advance this burgeoning category

More Than Movember: The Critical State Of Men’s Mental Health

75% of suicides in the West are male. Isn’t it time we thought more creatively about solutions to this global health crisis?

Hims Launches Hers, A Direct-To-Consumer Site Selling Birth Control And Other Drugs

Men’s wellness brand Hims is launching a sister brand, Hers, selling acne creams, vitamins and one medication that’s faced a fair share of controversy.

The New Anti-Flu Drug Xofluza’s Value Proposition

An improved clinical benefit profile together with the potential for diminished physician service and hospital spending appear to justify the Xofluza’s price premium relative to Tamiflu.

Anthem’s PBM On Track for 2020 Launch

Anthem said its own pharmacy benefit manager, IngenioRx, “remains on track” to launch Jan. 1, 2020.